FDA — authorised 15 November 2023
- Application: NDA214520
- Marketing authorisation holder: CORMEDIX
- Local brand name: DEFENCATH
- Indication: SOLUTION — N/A
- Status: approved
🇺🇸 Taurolidine and Heparin in United States
FDA authorised Taurolidine and Heparin on 15 November 2023
Marketing authorisations
FDA
- Status: approved
Taurolidine and Heparin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Taurolidine and Heparin approved in United States?
Yes. FDA authorised it on 15 November 2023; FDA has authorised it.
Who is the marketing authorisation holder for Taurolidine and Heparin in United States?
CORMEDIX holds the US marketing authorisation.